condition Oncology

Overview

Oncology is the branch of medicine that studies and treats cancers. Cancer is an umbrella term for a large group of diseases in which some cells grow too fast and spread to other parts of the body. Some cancers form tumors while others stay in the blood. Symptoms vary from cancer to cancer. Because cancer is such a complicated disease, a patient usually has a group of different doctors and specialists working as a team to manage their care. Treatments, like symptoms, vary from cancer to cancer. Common treatments include radiation, surgery, and chemotherapy. Newer options, like gene therapy, are being developed. No matter the treatment, most patients often need other medications to manage symptoms like nausea and low blood counts.

Drug Therapies

Alvaiz (eltrombopag choline)

Alvaiz (eltrombopag choline) is a TPO-receptor agonist approved to increase platelet production in patients with immune thrombocytopenia, aplastic anemia, or hepatitis C to facilitate the use of other medications.

Manufacturer:

Teva

Route of Administration:

Oral

Site of Care:

Outpatient

Website:

https://www.alvaiz.com

phone:

844-248-7949

Enrollment Forms:

Synergen Prescription Form

Patient Support Form

Approved Indication:

treatment of thrombocytopenia in adult and pediatric patients 6 years and older with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy and who are at an increased risk for bleeding

treatment of thrombocytopenia in adult patients with chronic hepatitis C to allow the initiation of interferon-based therapy

treatment of adult patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy

Conditions:

Immune Thrombocytopenia

Aplastic Anemia

Therapeutic Area:

Oncology

less details
Amitiza (lubiprostone)

(Amitiza) lubiprostone is a secretagogue approved by the FDA to increase the amount of water in the intestines to improve constipation and decrease abdominal pain. Amitiza must be taken with food.

Manufacturer:

Misc

Route of Administration:

Oral

Site of Care:

Outpatient

Website:

Enrollment Forms:

Synergen Prescription Form

Approved Indication:

treatment of irritable bowel syndrome with constipation in women 18 years of age and older

treatment of chronic idiopathic constipation in adults

treatment of opioid-induced constipation in adult patients with chronic, non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not required frequent opioid dose escalation

Conditions:

Irritable Bowel Syndrome with Constipation (IBS-C)

Chronic Idiopathic Constipation (CIC)

Opioid-Induced Constipation (OIC)

Therapeutic Area:

Gastroenterology

less details
Cresemba (isavuconazonium sulfate)

Cresemba (isavuconazonium sulfate) is an azole antifungal medication given orally or intravenously to treat invasive aspergillosis or invasive mucormycosis.

Manufacturer:

Astellas

Route of Administration:

Oral, Intravenous

Site of Care:

Outpatient

Website:

https://www.cresemba.com/

phone:

1-800-477-6472

Enrollment Forms:

Synergen Prescription Form

Patient Support Form

Approved Indication:

treatment of invasive aspergillosis and invasive mucormycosis in adults and pediatric patients 6 years of age and older who weigh at least 16 kilograms

Conditions:

Invasive Aspergillosis

Mucormycosis

less details
Fulphila (pegfilgrastim-jmdb)

Fulphila (pegfilgrastim-jmdb) is an FDA-approved biosimilar to Neulasta. Like Neulasta, Fulphila is a leukocyte growth factor that stimulates blood cell production.

Manufacturer:

Biocon Biologics

Route of Administration:

Subcutaneous

Site of Care:

Outpatient

Website:

https://fulphila.com/

phone:

1-833-695-2623

Enrollment Forms:

Synergen Prescription Form

Patient Support Form

Approved Indication:

to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of febrile neutropenia

Conditions:

Neutropenia Associated with Myelosuppressive Anti-Cancer Therapy

Therapeutic Area:

Oncology

less details
Fylnetra (pegfilgrastim-pbbk)

Fylnetra (pegfilgrastim-pbbk) is an FDA-approved biosimilar to Neulasta. Like Neulasta, Fylnetra is a leukocyte growth factor that stimulates blood cell production.

Manufacturer:

Amneal Pharmaceuticals

Route of Administration:

Subcutaneous

Site of Care:

Outpatient

Website:

https://fylnetra.us/

phone:

866-4AMNEAL (866-426-6325)

Enrollment Forms:

Synergen Prescription Form

Patient Support Form

Approved Indication:

to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of febrile neutropenia

to increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome)

Conditions:

Neutropenia Associated with Myelosuppressive Anti-Cancer Therapy

Hematopoietic Syndrome of Acute Radiation Syndrome

Therapeutic Area:

Oncology

less details
Granix (tbo-filgrastim)

Granix (tbo-filgrastim) is a colony-stimulating factor that increases circulating levels of neutrophils, a type of white blood cell.

Manufacturer:

Teva

Route of Administration:

Subcutaneous

Site of Care:

Outpatient

Website:

https://www.granixhcp.com/

Enrollment Forms:

Synergen Prescription Form

Patient Support Form

Approved Indication:

for reduction in the duration of severe neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia in adult and pediatric patients 1 month and older

Conditions:

Neutropenia Associated with Myelosuppressive Anti-Cancer Therapy

Therapeutic Area:

Oncology

less details
Livtencity (maribavir)

Livtencity (maribavir) is an antiviral medication approved by the FDA to treat infection with cytomegalovirus (CMV) in patients who have received a transplant and have failed or are resistant to other antivirals.

Manufacturer:

Takeda

Route of Administration:

Oral

Site of Care:

Outpatient

Website:

https://www.livtencity.com/

phone:

1-855-268-1825

Enrollment Forms:

Synergen Prescription Form

Patient Support Form

Approved Indication:

treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant CMV infection/disease that is refractory to treatment (+/- genotypic resistance) with ganciclovir, valganciclovir, cidofovir, or foscarnet

Conditions:

Post-Transplant Cytomegalovirus (CMV) Infection

Therapeutic Area:

Infectious disease

less details
Movantik (naloxegol)

Movantik (naloxegol) is a version of naloxone designed to relieve the constipation caused by long-term use of opioid pain medications without interfering with pain management.

Manufacturer:

Valinor Pharma | AstraZeneca

Route of Administration:

Oral

Site of Care:

Outpatient

Website:

https://movantik.com/hcp/

Enrollment Forms:

Synergen Prescription Form

Approved Indication:

treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation

Conditions:

Opioid-Induced Constipation (OIC)

Therapeutic Area:

Gastroenterology

less details
Nivestym (filgrastim-aafi)

Nivestym (filgrastim-aafi) is an FDA-approved biosimilar to Neupogen. Like Neupogen, Nivestym is a leukocyte growth factor that stimulates blood cell production and can be used to prepare a patient for a bone marrow transplant.

Manufacturer:

Pfizer

Route of Administration:

Subcutaneous

Site of Care:

Outpatient

Website:

https://www.pfizer.com/products/product-detail/nivestym

phone:

1-877-744-5675

Enrollment Forms:

Synergen Prescription Form

Patient Support Form

Approved Indication:

to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever

to reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML)

to reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with non-myeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT)

to mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis

to reduce the incidence and duration of sequelae of severe neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia

Conditions:

Neutropenia Associated with Myelosuppressive Anti-Cancer Therapy

Hematopoietic Stem Cell Transplantation

Cyclic/Congenital/Idiopathic Neutropenia

Therapeutic Area:

Oncology

less details
Nplate (romiplostim)

Nplate (romiplostim) is an agonist of the thrombopoietin receptor approved to help increase platelet levels in patients with immune thrombocytopenia.

Manufacturer:

Amgen

Route of Administration:

Subcutaneous

Site of Care:

Outpatient

Website:

https://www.nplate.com

phone:

866-264-2778

Enrollment Forms:

Synergen Prescription Form

Patient Support Form

Approved Indication:

treatment of thrombocytopenia in adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy

treatment of thrombocytopenia in pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy

to increase survival in adults and in pediatric patients (including term neonates) acutely exposed to myelosuppressive doses of radiation

Conditions:

Immune Thrombocytopenia

Hematopoietic Syndrome of Acute Radiation Syndrome

less details
Nyvepria (pegfilgrastim-apgf)

Nyvepria (pegfilgrastim-apgf) is an FDA-approved biosimilar to Neulasta. Like Neulasta, Fylnetra is a leukocyte growth factor that stimulates blood cell production.

Manufacturer:

Pfizer

Route of Administration:

Subcutaneous

Site of Care:

Outpatient

Website:

https://www.pfizer.com/products/product-detail/nyvepriatm

phone:

1-877-744-5675

Enrollment Forms:

Synergen Prescription Form

Patient Support Form

Approved Indication:

to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia

Conditions:

Neutropenia Associated with Myelosuppressive Anti-Cancer Therapy

Therapeutic Area:

Oncology

less details
posaconazole

Posaconazole is an azole antifungal medication given orally to treat Candida infections of the mouth or throat or orally or intravenously to prevent Aspergillus or Candida infections in patients with compromised immune systems.

Manufacturer:

Misc

Route of Administration:

Oral

Site of Care:

Outpatient

Website:

Enrollment Forms:

Synergen Prescription Form

Approved Indication:

prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant recipients with graft-versus-host disease or those with hematologic malignancies with prolonged neutropenia from chemotherapy

treatment of oropharyngeal candidiasis (OPC), including OPC refractory to itraconazole and/or fluconazole

Conditions:

Aspergillosis

Candidiasis

less details
Prevymis (letermovir)

Prevymis (letermovir) is an antiviral medication given intravenously or by mouth to prevent infection with cytomegalovirus (CMV) in patients who have received a transplant.

Manufacturer:

Merck

Route of Administration:

Oral

Site of Care:

Outpatient

Website:

https://www.prevymis.com/

phone:

855-404-5278

Enrollment Forms:

Synergen Prescription Form

Patient Support Form

Approved Indication:

prophylaxis of cytomegalovirus (CMV) infection and disease in adult and pediatric patients 6 months of age and older weighing at least 6 kg who are CMV-seropositive recipients [R+] of an allogenic hematopoietic stem cell transplant

prophylaxis of CMV disease in adult and pediatric patients 12 years of age and older and weighing at least 40 kg who are kidney transplant recipients at high risk (donor CMV seropositive/recipient CMV seronegative [D+/R-])

Conditions:

Post-Transplant Cytomegalovirus (CMV) Prophylaxis

Therapeutic Area:

Infectious disease

less details
Promacta (eltrombopag olamine)

Promacta (eltrombopag) is an agonist of the thrombopoietin receptor approved to help increase platelet levels in patients with advanced liver disease or aplastic anemia.

Manufacturer:

Novartis

Route of Administration:

Oral

Site of Care:

Outpatient

Website:

https://us.promacta.com

phone:

1-877-577-7756

Enrollment Forms:

Synergen Prescription Form

Patient Support Form

Approved Indication:

treatment of thrombocytopenia in adult and pediatric patients 1 year and older with persistent or chronic imune thrombocytopenia who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy and whose degree of thrombocytopenia and clinical condition increases the risk for bleeding

treatment of thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy when the degree of thrombocytopenia prevents the ability to initiate or maintain interferon-based therapy

in combination with standard immunosuppressive therapy for first-line treatment of adult and pediatric patients 2 years and older with severe aplastic anemia

treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy

Conditions:

Thrombocytopenia

Aplastic Anemia

Therapeutic Area:

Hepatology
Oncology

less details
Releuko (filgrastim-ayow)

Releuko (filgrastim-ayow) is an FDA-approved biosimilar to Neupogen. Like Neupogen, Releuko is a leukocyte growth factor that stimulates blood cell production, but Releuko is not approved for stem cell mobilization prior to a bone marrow transplant.

Manufacturer:

Amneal Pharmaceuticals

Route of Administration:

Subcutaneous

Site of Care:

Outpatient

Website:

https://releuko.us/

phone:

866-4AMNEAL (866-426-6325)

Enrollment Forms:

Synergen Prescription Form

Patient Support Form

Approved Indication:

to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever

to reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML)

to reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with non-myeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT)

to mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis

to reduce the incidence and duration of sequelae of severe neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia

to increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome)

Conditions:

Neutropenia Associated with Myelosuppressive Anti-Cancer Therapy

Hematopoietic Stem Cell Transplantation

Cyclic/Congenital/Idiopathic Neutropenia

Hematopoietic Syndrome of Acute Radiation Syndrome

Therapeutic Area:

Oncology

less details
Relistor (methylnaltrexone)

Relistor (methylnaltrexone) is a modified version of naltrexone designed to relieve the constipation caused by long-term use of opioid pain medications without interfering with pain management.

Manufacturer:

Salix Pharmaceuticals

Route of Administration:

Oral, Subcutaneous

Site of Care:

Outpatient

Website:

https://www.relistor.com/

Enrollment Forms:

Synergen Prescription Form

Approved Indication:

[tablets and injection] treatment of opioid-induced constipation in adults with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation

[injection] treatment of opioid-induced constipation in adult with advanced illness or pain caused by active cancer who require opioid dosage escalation for palliative care

Conditions:

Opioid-Induced Constipation (OIC)

Therapeutic Area:

Gastroenterology

less details
Symproic (naldemedine)

Symproic (naldemedine) is a version of naltrexone designed to relieve the constipation caused by long-term use of opioid pain medications without interfering with pain management.

Manufacturer:

Collegium

Route of Administration:

Oral

Site of Care:

Outpatient

Website:

https://www.symproic.com

Enrollment Forms:

Synergen Prescription Form

Approved Indication:

treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation

Conditions:

Opioid-Induced Constipation (OIC)

Therapeutic Area:

Gastroenterology

less details
Udenyca (pegfilgrastim-cbqv)

Udenyca (pegfilgrastim-cbqv) is an FDA-approved biosimilar to Neulasta. Like Neulasta, Fylnetra is a leukocyte growth factor that stimulates blood cell production.

Manufacturer:

Coherus BioSciences

Route of Administration:

Subcutaneous

Site of Care:

Outpatient

Website:

https://www.udenyca.com/hcp

phone:

1-844-483-3692

Enrollment Forms:

Synergen Prescription Form

Patient Support Form

Approved Indication:

to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of febrile neutropenia

to increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome)

Conditions:

Neutropenia Associated with Myelosuppressive Anti-Cancer Therapy

Hematopoietic Syndrome of Acute Radiation Syndrome

Therapeutic Area:

Oncology

less details
valacyclovir

Valacyclovir is an antiviral medication used to treat or prevent infections by various strains of the herpes virus.

Manufacturer:

Misc

Route of Administration:

Oral

Site of Care:

Outpatient

Website:

Enrollment Forms:

Synergen Prescription Form

Approved Indication:

cold sores (Herpes labialis) in adult and pediatric patients

treatment of initial or recurrent genital herpes in immunocompetent adult patients

suppression of genital herpes in immunocompent or HIV-infected adult patients

reduction of transmission of genital herpes in adult patients

Herpes zoster in adult patients

chickenpox in pediatric patients

Conditions:

Herpes Labialis Infection

Herpes Zoster Infection

Genital Herpes

Cold Sores

Chickenpox

Therapeutic Area:

Infectious Disease

less details
valganciclovir

Valganciclovir is an antiviral medication that targets cytomegalovirus (CMV) and is used to treat and/or prevent CMV infection in patients who have received a transplant.

Manufacturer:

Misc

Route of Administration:

Oral

Site of Care:

Outpatient

Website:

Enrollment Forms:

Synergen Prescription Form

Approved Indication:

treatment of cytomegalovirus retinitis in adult patients with acquired immunodeficiency syndrome (AIDS)

prevention of cytomegalovirus disease in adult kidney, heart, or kidney-pancrease transplant patients at high risk

prevention of cytomegalovirus disease in pediatric kidney or heart transplant patients at high risk

Conditions:

Cytomegalovirus

Therapeutic Area:

Infectious Disease

less details
voriconazole

Voriconazole is a triazole antifungal agent given intravenously or by mouth to treat invasive fungal infections caused by Aspergillus sp, Candida sp, Fusarium sp, and others. In immunocompromised patients, voriconazole is also used to prevent these infections.

Manufacturer:

Misc

Route of Administration:

Oral, Intravenous

Site of Care:

Outpatient

Website:

Enrollment Forms:

Synergen Prescription Form

Approved Indication:

treatment of invasive aspergillosis

treatment of Candidemia in nonneutropenic patients and the following Candida infections: disseminated infections in skin and infections in abdomen, kidney, bladder wall, and wounds

treatment of esophageal candidiasis

treatment of serious fungal infections caused by Scedosporium apiospermum and Fusium spp. in patients intolerant of or refractory to other therapy

Conditions:

Aspergillosis

Candidiasis

Therapeutic Area:

Infectious Disease

less details

Resources

Understanding a diagnosis can feel overwhelming. These resources link to well-established organizations, for in-depth education, research, and support.

American Cancer Society

National Cancer Institute

Stay Connected

Get the latest news and updates

condition Oncology

Overview

Drug Therapies

Alvaiz (eltrombopag choline)

Approved Indication:

Conditions:

Therapeutic Area:

Amitiza (lubiprostone)

Approved Indication:

Conditions:

Therapeutic Area:

Cresemba (isavuconazonium sulfate)

Approved Indication:

Conditions:

Fulphila (pegfilgrastim-jmdb)

Approved Indication:

Conditions:

Therapeutic Area:

Fylnetra (pegfilgrastim-pbbk)

Approved Indication:

Conditions:

Therapeutic Area:

Granix (tbo-filgrastim)

Approved Indication:

Conditions:

Therapeutic Area:

Livtencity (maribavir)

Approved Indication:

Conditions:

Therapeutic Area:

Movantik (naloxegol)

Approved Indication:

Conditions:

Therapeutic Area:

Nivestym (filgrastim-aafi)

Approved Indication:

Conditions:

Therapeutic Area:

Nplate (romiplostim)

Approved Indication:

Conditions:

Nyvepria (pegfilgrastim-apgf)

Approved Indication:

Conditions:

Therapeutic Area:

posaconazole

Approved Indication:

Conditions:

Prevymis (letermovir)

Approved Indication:

Conditions:

Therapeutic Area:

Promacta (eltrombopag olamine)

Approved Indication:

Conditions:

Therapeutic Area:

Releuko (filgrastim-ayow)

Approved Indication:

Conditions:

Therapeutic Area:

Relistor (methylnaltrexone)

Approved Indication:

Conditions:

Therapeutic Area:

Symproic (naldemedine)

Approved Indication:

Conditions:

Therapeutic Area:

Udenyca (pegfilgrastim-cbqv)

Approved Indication:

Conditions:

Therapeutic Area:

valacyclovir

Approved Indication:

Conditions:

Therapeutic Area:

valganciclovir

Approved Indication:

Conditions:

Therapeutic Area: